Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies

• Published in: BMC cancer 2021-05, Vol.21 (1), p.618-13, Article 618
• Main Authors: Zhang, Ting, Sun, Jing, Li, Jinying, Zhao, Yunuo, Zhang, Tao, Yang, Ruoning, Ma, Xuelei
• Format: Article
• Language: English
• Subjects: Adverse events; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antitumor activity; Bias; Cancer; Cancer therapies; Care and treatment; CCL17 protein; CCL22 protein; CCR4; Chemokine receptors; Chemokines; Clinical trials; Drug dosages; Drug-Related Side Effects and Adverse Reactions - epidemiology; Drug-Related Side Effects and Adverse Reactions - etiology; Evaluation; Exanthema; Fever; Humans; Immune response; Immunoglobulin G; Immunosuppressive agents; Immunotherapy; Leukopenia; Ligands; Lymphocytes T; Lymphoma; Lymphopenia; Malignant lymphoma; Management; Meta-analysis; Mogamulizumab; Monoclonal antibodies; Neoplasms - drug therapy; Neoplasms - mortality; Neutropenia; Oncology, Experimental; Prognosis; Progression-Free Survival; Randomized Controlled Trials as Topic; Receptors, CCR4 - antagonists & inhibitors; Secondary data analysis; Solid tumors; T-cell lymphoma; Targeted cancer therapy; Toxicity; Tumor cells
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-021-08363-w

CC chemokine receptor 4 (CCR4), the receptor for CCL22 and CCL17, is expressed on the surface of effector Tregs that have the highest suppressive effects on antitumor immune response. CCR4 is also widely expressed on the surface of tumor cells from patients with adult T-cell leukemia/lymphoma (ATL), peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). Mogamulizumab is a humanized, IgG1 kappa monoclonal antibody that is directed against CCR4. By reducing the number of CCR4-positive Tregs and tumor cells, the mogamulizumab can reduce tumor burden and boost antitumor immunity to achieve antitumor effects. We examined the PubMed and ClinicalTrials.gov until 1 February 2020. Considering variability in different studies, we selected the adverse events (AEs), overall survival (OS), progression-free survival (PFS), objective responses rate (ORR) and Hazard Ratio (HR) for PFS to evaluate the safety and efficacy profile of mogamulizumab. When patients were treated with mogamulizumab monotherapy, the most common all-grade AEs were lymphopenia, infusion reaction, fever, rash and chills while the most common grade ≥ 3 AEs were lymphopenia, neutropenia and rash. When patients were treated with combined therapy of mogamulizumab and other drugs, the most common all-grade AEs were neutropenia, anaemia, lymphopenia and gastrointestinal disorder, while the most common grade ≥ 3 AEs was lymphopenia. For patients treated with mogamulizumab monotherapy, the pooled ORR and mean PFS were 0.430 (95% CI: 0.393-0.469) and 1.060 months (95% CI: 1.043-1.077), respectively. For patients treated with combined therapy of mogamulizumab and other drugs, the pooled ORR was 0.203 (95% CI: 0.022-0.746) while the pooled PFS and OS were 2.093 months (95% CI: 1.602-2.584) and 6.591 months (95% CI: 6.014-7.167), respectively. Based on present evidence, we believed that mogamulizumab had clinically meaningful antitumor activity with acceptable toxicity which is a novel therapy in treating patients with cancers.